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Neuroprotective Potential of Astroglia
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Astroglia are the homoeostatic cells of the central ner-
vous system, which participate in all essential functions
of the brain. Astrocytes support neuronal networks by
handling water and ion fluxes, transmitter clearance, pro-
vision of antioxidants, and metabolic precursors and
growth factors. The critical dependence of neurons on
constant support from the astrocytes confers astrocytes
with intrinsic neuroprotective properties. On the other
hand, loss of astrocytic support or their pathological
transformation compromises neuronal functionality and
viability. Manipulating neuroprotective functions of astro-
cytes is thus an important strategy to enhance neuronal
survival and improve outcomes in disease states. VC 2017
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INTRODUCTION
The definition of “an astrocyte” is complicated and
continues to be shaped by the ongoing discoveries involv-
ing glia in the central nervous system (CNS). The word
“astrocyte” was originally applied by Michael von Len-
hossek in 1891 to the numerous star-shaped cells observed
in histological brain specimens, once it had been realized
that “neuroglia” (brain glue) was composed of individual
cellular elements (Lenhossek, 1891). Astrocytes are now
recognized as a heterogenous population based on their
morphology and the expression of different sets of recep-
tors, transporters, ion channels, and other proteins
(Matyash and Kettenmann, 2010; Oberheim et al., 2012;
Bribian et al., 2015). This raises the intriguing possibility
that different subtypes and lineages of astrocytes could be
implicated in distinct metabolic/homeostatic functions
and suggests that astrocytes can be specialized to serve the
functions of various neuronal subpopulations. Moreover,
recent studies suggest that astrocytes may exist in differ-
ent, fairly stable functional states in terms of their interac-
tion with neurons and, under some conditions, may
become dangerously neurotoxic (Liddelow et al., 2017;
Lin et al., 2017).
If astrocytes are heterogenous, how do we unequiv-
ocally distinguish them from other cell types? Mature
astrocytes are usually anatomically classified into two gen-
eral categories: protoplasmic and fibrous (Sofroniew and
Vinters, 2010; Oberheim et al., 2012). Protoplasmic
astroglial cells are found in gray matter tissue in close asso-
ciation with neurons. They possess a larger quantity of
organelles and have relatively thicker, shorter, highly
branched processes. Some of these processes closely asso-
ciate with neuronal synapses, while others extend toward
blood vessels. Fibrous astrocytes are present in white mat-
ter and have relatively few organelles, fewer but longer
processes that extend along axon bundles, providing
structural and metabolic support for the axonal tracts. For
decades, identification of astrocytes was based on the use
of antibodies that recognize astrocyte-specific proteins,
but immunohistochemistry is now increasingly supple-
mented by the use of the promoters of some of these
genes to drive expression of various marker proteins in
these cells without staining and even in the brain in situ.
By far the most widely used immunohistochemical
marker is glial fibrillary acidic protein (GFAP), which was
the first widely accepted marker (Brenner et al., 1994;
Lee et al., 2008) and has stood the test of time well. Up
to this day, cells that robustly express GFAP are
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commonly identified as astrocytes. The converse, how-
ever, does not appear to be correct. Many mature astro-
cytes do not express detectable levels of GFAP (e.g., in
the rodent cortex), and GFAP expression by astrocytes
exhibits both regional and local variability that is dynami-
cally regulated by a large number of inter- and intracellu-
lar signaling molecules (Morrison et al., 1985; Lee et al.,
2006; Oberheim et al., 2012). Therefore, it is important
to recognize the limitations of GFAP as an astrocyte
marker (Kimelberg, 2004; Sofroniew, 2009). Other
molecular markers that have been used for immunohisto-
chemical identification of astrocytes include glutamine
synthetase (GS), the Ca21-binding protein S100b, and
the glutamate transporters EAAT1 and EAAT2 (excit-
atory amino acid transporters, in humans), known as
GLAST (glutamate aspartate transporter) and GLT1 (glu-
tamate transporter 1) in rodents (Norenberg, 1979; Gon-
calves et al., 2008). Several recent studies have conducted
large-scale genetic analyses of the astrocyte transcriptomes
in rodents and humans and have identified large numbers
of molecules enriched in astrocytes (Cahoy et al., 2008;
Zhang et al., 2014). Such studies help to identify potential
candidates for new and possibly better molecular markers
for astrocytes. An interesting addition to the pool of astro-
cytic markers is SOX9, a transcriptional factor that has
been reported as selective for astrocytes in most brain
areas (Sun et al., 2017). This protein is characteristically
accumulated in the nuclei of the cells, which sometimes is
very useful when, for example, one needs to count astro-
cytes, which is not a trivial task using antibodies against
GFAP that predominantly stain processes, creating a
mesh-like staining pattern.
An alternative to reliance on immunocytochemical
staining of markers is to express a fluorescent molecule,
such as GFP, using astrocyte-specific promoters. This tech-
nique allows the cells to be identified and studied in the liv-
ing tissue. Several promoters have been used to achieve this
effect, some driving EGFP directly, others driving expres-
sion of CRE, which requires a cross with a CRE-
dependent reporter mouse. GFAP promoter was the first
one used for this purpose (Brenner et al., 1994; Nolte et al.,
2001), and mice based on this promoter are still used
widely, even though some publications have questioned the
specificity of expression in these animals (Fujita et al.,
2014). More recently, however, other (perhaps better) driv-
ers of highly specific expression were found for astrocytes.
For example, very recent studies employed Aldh1l1-EGFP
mice (Liddelow et al., 2017; Lin et al., 2017). We would
like to emphasize that expression of the proteins responsible
for most cellular activities changes under various conditions,
and therefore the activity of all promoters is variable; this
can affect the interpretation of the results.
Electrophysiological approaches played an important
part in the study of neurons but less so in the identification
and investigation of astrocytes. Because of their leaky K1
channels, mature astrocytes have very negative membrane
potentials and are electrically passive (i.e., do not generate
action potentials). Very low membrane resistance also
means that recordings made from the somata of astrocytes
do not reveal local currents mediated by events in their
remote processes. However, the lack of action potentials
in astrocytes does not mean they are physiologically
“silent.” To the contrary, astrocytes are highly chemically
excitable cells. Astrocytes express numerous metabotropic
receptors and commonly respond to signaling molecules
(neurotransmitters) by dynamic changes in the cytoplasmic
concentration of two cations, Ca21 and Na1 (Agulhon
et al., 2008; Gourine et al., 2010; Parpura and Verkhrat-
sky, 2012; Turovsky et al., 2016). Neuronal activity can
trigger complex spatiotemporal changes of [Ca21]i and
[Na1]i in astrocytes and generate propagating Ca21 or
Na1 waves, which in turn regulate multiple effector path-
ways in these glial cells (Bernardinelli et al., 2004; Agulhon
et al., 2008, 2012; Gourine et al., 2010; Rose and Verkh-
ratsky, 2016). Astrocytes are also highly mechanosensitive,
a well-known feature whose physiological significance is
not yet understood (Araque et al., 1998; Paemeleire and
Leybaert, 2000; Maneshi et al., 2017).
It is becoming increasingly clear that even though
gray matter astrocytes from various parts of the brain may
look indistinguishable, they are, in fact, physiologically
diverse. For example, we demonstrated that astrocytes
located on the ventral surface of the medulla are involved
in central respiratory control and highly sensitive to subtle
changes in pH, but cortical astrocytes are not (Gourine
et al., 2010). More recently, we found that this sensitivity
to pH could be mediated by the electrogenic Na1/HCO23
cotransporter NBCe1, which is enriched in this population
of astrocytes and is responsible for the acidification-induced
influx of Na1, eventually leading to Ca21 elevation and
release of ATP (Turovsky et al., 2016).
Attempts to stratify astrocytes are ongoing.
Recently, using astrocytes isolated from the Aldh1l1-
EGFP reporter mouse, Lin et al. demonstrated that by
using antibodies against CD51, CD63, and CD71, it is
possible to subdivide astrocytes into several categories
with fluorescence-activated cell sorting based on combi-
nations of expression of these three markers (Lin et al.,
2017). In their experiments, five classes of cells were sepa-
rated using this combinatorial approach. They were also
different in terms of their transcriptomes and their ability
to support synaptogenesis. Moreover, to some extent
these molecular signatures could be even traced in malig-
nant gliomas, potentially indicating a relationship of some
astrocyte populations with glioma. It would be very inter-
esting to know whether there are differences in the neu-
roprotective potential of these proposed subpopulations of
astrocytes. Another obvious question concerns the extent
to which the genetic profile of the astrocyte is set by the
neurons with which it directly interacts, and whether
astrocytes can be fine-tuned to “look after” various types
of neurons (e.g., cortical pyramidal neurons) versus inter-
neurons versus dopaminergic neurons, and so forth. A
very elegant approach to this question has been recently
described by Hasel et al., who reported that neuronal
activity shapes the genomic profile of co-cultured astro-
cytes (Hasel et al., 2017). The idea in that study was to
use co-cultures of neurones and astrocytes from different
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species. This allows in silico discrimination of the changes
in gene expression in individual cell populations using
next-generation sequencing by mapping individual tran-
scripts to one of the two species. Since the origins of
astrocytes and neurones are known, the authors could
allocate altered genes to one or the other cell type.
NEUROPROTECTIVE MECHANISMS IN
ASTROCYTES
Astrocytes Take Up Neurotransmitters
Gamma-aminobutyric acid (GABA) and glutamate
are the main fast inhibitory and excitatory neurotransmit-
ters in the mammalian brain that are released mainly from
presynaptic boutons/terminals (Danbolt, 2001; Foster and
Kemp, 2006; Schousboe and Waagepetersen, 2007).
Transmitter concentration determines the extent of
receptor activation and signal transmission. It is of critical
importance that the resting extracellular concentrations of
signaling molecules are kept low (Zhou and Danbolt,
2013). Low extracellular levels can only be maintained by
cellular uptake because there is no extracellular metabo-
lism of GABA and glutamate. In case of glutamate, there
is an important reason to keep the extracellular levels low.
It is generally known that overstimulation by glutamate
induces excitotoxicity, a well-recognized component of
the pathogenesis of many brain disorders (Platt, 2007;
Broer and Palacin, 2011; Lai et al., 2014; Takahashi et al.,
2015). Clearing neurotransmitters from the extracellular
space is one of the astrocytes’ most critical functions.
Astrocytes take up glutamate using two main transport-
ers—EAAT1/GLAST and EAAT2/GLT1 (Rothstein
et al., 1996; Danbolt, 2001; Zhou and Danbolt, 2013;
Jensen et al., 2015). Rothstein et al. showed that loss of
astrocytic GLAST or GLT1 led to elevated extracellular
glutamate levels, excitotoxic neurodegeneration, and pro-
gressive paralysis (Rothstein et al., 1996). In another
study, glutamate uptake activity in GLT1 knockout mice
was reduced by about 95%. About half of mice died from
spontaneous seizures before they reached 4 weeks of age
(Tanaka et al., 1997). Interestingly, lack of GLAST does
not lead to spontaneous seizures like those seen in GLT1-
deficient mice, but when seizures are initiated, lack of
GLAST increases the seizure duration and severity (Wata-
nabe et al., 1999). The difference in mice lacking either
GLT1 or GLAST might be due to the brain-specific
localization of both transporters. Multiple studies have
demonstrated significant regional heterogeneity in the
expression of the two glutamate transporters in CNS
(Torp et al., 1997; Berger and Hediger, 2000). It is worth
mentioning that glioma cells, with the majority believed
to originate from astrocytes (Kleihues et al., 1995), lack
the expression of EAAT2. And EAAT1 is mislocalized to
the nuclear membrane (Ye et al., 1999). This leads to an
almost complete absence of glutamate uptake into glioma
cells. Even more surprisingly, these cells actually release
glutamate, which causes excitotoxic damage to the sur-
rounding neurons. This to some extent explains the for-
mation of seizure activity in the tissue surrounding
tumors, a common symptom early in the course of disease
(de Groot and Sontheimer, 2011).
Astrocytes do not destroy glutamate but, in effect,
return it to neurons via the well-established glutamate–
glutamine cycle (Bak et al., 2006). In brief, glutamate is
converted to glutamine by the astrocyte-specific enzyme
GS. Glutamine is then transferred to neurons, where it is
converted back to glutamate via deamidation by
phosphate-activated glutaminase, which is enriched in the
neuronal compartment. Failure to do so would result in
the rapid depletion of the glutamate pool in presynaptic
terminals and subsequent disruption of excitatory neuro-
transmission (Hertz et al., 1999; Tani et al., 2014). Astro-
glial glutamine is also critical for GABA replenishment in
GABAergic neurons. Presynaptic terminals convert gluta-
mine to glutamate, which is then metabolized into GABA
by glutamate decarboxylase. This is known as the GABA–
glutamine cycle (Walls et al., 2015). Because inhibition in
the brain critically depends on GABA, insufficient supply
of glutamine to GABAergic neurons may result in seizures
(Eid et al., 2013). Although the most common disorder
associated with insufficient GABA activity is epilepsy,
many other neuropsychiatric diseases involve GABAergic
dysfunction as a component (Wong et al., 2003; Gajcy
et al., 2010). As GS is an essential part of the glutamine–
glutamate/GABA cycle, it is not hard to see why changes
in expression and activity of GS may lead to neurological
dysfunction (Eid et al., 2004; Steffek et al., 2008; Lee
et al., 2010; Rose et al., 2013). Astrocyte-specific elimi-
nation of GS in neonatal mice led to a progressive failure
to feed, which caused death due to hypoglycemia within
3 days after birth. Death was associated with a precipitous
decline in the concentration of glutamine (He et al.,
2010).
Astrocytes are also responsible for replenishment of
the overall brain pool of glutamate, as they are the only
neural cell type expressing pyruvate carboxylase, a key
enzyme converting pyruvate into oxaloacetate and a
downstream intermediate, 2-oxoglutarate (Shank et al.,
1985; Olsen and Sonnewald, 2014). Glutamate is then
synthesized from 2-oxoglutarate by transamination of
aspartate. This is an essential anaplerotic pathway in the
brain, which effectively allows astrocytes to synthesize
new glutamate from glucose.
To summarize, astrocytes, on one hand, are respon-
sible for the elimination of glutamate from the extracellu-
lar space, creating an environment for effective
glutamatergic signaling; on the other hand, they support
turnover of glutamate and replenish its stocks.
Astrocytes Regulate Ion Homeostasis and pH
Ion and volume homeostasis in the CNS is main-
tained by a number of mechanisms, residing mainly in
glial cells. Apart from the release of neurotransmitters,
neuronal activity and action potentials cause substantial
local increases of extracellular K1 in the restricted extra-
cellular space (Heinemann and Lux, 1977). Without tight
regulatory mechanisms, this could dramatically alter the
2128 Liu et al.
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neuronal membrane potential, leading to hyperexcitabil-
ity. Such a scenario is prevented by the buffering of extra-
cellular K1 by glial cells. Indeed, astrocytes have a
strongly negative resting potential and express a large
number of K1 channels, resulting in high membrane K1
permeability (Orkand et al., 1966; Barres, 1991). This, in
conjunction with the action of the Na1/K1 ATPase,
enables astrocytes to capture the excess of extracellular
K1, which can then travel in the astrocytic syncytium
through gap junctions down its concentration gradient
(the so-called potassium-siphoning mechanism). In the-
ory, this should allow a flux of K1 from areas of its high
concentration toward areas of lower concentration where
it can be extruded either into the extracellular space or
into the circulation (Newman, 1987; Chen and Nichol-
son, 2000; Kofuji and Newman, 2004; Belanger and
Magistretti, 2009). Astrocytic Kir4.1 channels seem to be
particularly important for K1 buffering (Takumi et al.,
1995; Higashi et al., 2001; Djukic et al., 2007). Downre-
gulation of Kir4.1 by RNAi led to a significant impair-
ment in K1 and glutamate buffering functions of
astrocytes, hyperexcitability of neurons, and abnormal
synaptic transmission (Kucheryavykh et al., 2007). In the
astrocyte-specific conditional Kir4.1 knockout mice,
capacity to regulate extracellular K1 and glutamate levels
is compromised (Djukic et al., 2007; Chever et al., 2010).
M. Nedergaard’s group demonstrated that ammonia trig-
gers neurotoxicity by impairing astrocyte K1 buffering
(Rangroo Thrane et al., 2013). Aquaporin-4 (AQP4), the
predominant water channel expressed by astrocytes in the
CNS, has been shown to be colocalized with Kir4.1. The
colocalization of these two proteins suggests that AQP4
contributes to the coupled influx of water and K1 after
neuronal activity (Nagelhus et al., 1999; Potokar et al.,
2016). Kir4.1 expression is consistently decreased in a
variety of neurodegenerative diseases including amyotro-
phic lateral sclerosis, Alzheimer disease, Huntington dis-
ease, and Alexander disease (Nwaobi et al., 2016).
However, whether the reduction is a primary pathophysi-
ological contributor to disease progression or just repre-
sents a secondary response to neuroinflammation has yet
to be determined.
Another fundamental supportive function of astro-
cytes is their contribution to pH regulation (Belanger and
Magistretti, 2009). Many neuronal functions including
energy metabolism, membrane conductance, neuronal
excitability, synaptic transmission, and gap junction com-
munication are strongly affected by relatively small shifts
in pH (Deitmer and Rose, 1996; Obara et al., 2008). An
important feature of glial cells, endowing them with a
robust pH buffering capacity, is high expression of car-
bonic anhydrase, which converts CO2 into H
1 and
HCO23 —effectively allowing them to act as a CO2 sink
(Cammer and Tansey, 1988; Agnati et al., 1995). Regula-
tion of extracellular pH by astrocytes is carried out by
transport of H1 with Na1/H1 exchanger, by operation
of monocarboxylate transporters (MCTs) that cotransport
one H1 with one lactate molecule and by Na1/HCO23
exchanger (Deitmer and Rose, 2010) or cotransporter
(Song et al., 2013). Additionally, GLTs, which take up
glutamate, also cotransport protons (1:1) from the extra-
cellular milieu (Verkhratsky et al., 2015). In this context,
it is interesting that the astrocytes on the ventral surface of
the medulla overlaying the central chemoreceptor area are
intrinsically sensitive to CO2 and pH. It has been recently
demonstrated that Na1/HCO23 exchanger, which is par-
ticularly highly expressed in these cells, could act as an
acidification sensor, leading to an influx of Na1 with con-
secutive reversal of Na1/Ca21 exchanger, followed by
Ca21 entry and downstream signaling events (Turovsky
et al., 2016).
Finally, astrocytes may play a role in the regulation
of Ca21 concentrations. A decrease in extracellular Ca21
concentration due to high neuronal activity evokes
[Ca21]i increases in astrocytes, with some of this cytosolic
astrocytic Ca21 being excreted into the extracellular space
via Na1/Ca21 exchanger (Zanotti and Charles, 1997). It
was later shown that a drop in extracellular Ca21 due to
synaptic activity could evoke release of ATP from astro-
cytes, probably because of opening of the connexin 43
hemichannels. This process in some areas could lead to
increased activity of GABAergic neurons (Torres et al.,
2012).
Astrocytes Supply Neurons with Energy Substrates
Astrocytes make important contributions to CNS
metabolism. While the brain is a very energy-hungry
organ, it contains few energy reserves and is therefore
highly dependent on the uninterrupted supply of glucose
from the circulation. The morphological characteristics of
astrocytes are ideally tailored to sense neuronal activity at
the synapse and respond with the appropriate metabolic
supply via their end-feet, some of which also directly con-
tact intracerebral blood vessels (Belanger et al., 2011); this
idea dates back to the famous predictions made by
Ramon y Cajal (1913). Astrocytes have been proposed to
play an instrumental role in coupling neuronal activity
and brain glucose uptake through a mechanism referred
to as the “astrocyte–neuron lactate shuttle” proposed over
two decades ago by Pellerin and Magistretti (1994). The
essence of this model is that neuronal activity triggers glu-
cose metabolism in astrocytes. Glucose then undergoes
glycolysis, and the produced pyruvate is converted to lac-
tate, which is eventually released from astrocytes and
taken up by neurons to be used for oxidative phosphory-
lation (Pellerin and Magistretti, 1994; Fillenz, 2005). This
idea is still hotly debated; for further discussion, please see
our recent reviews (Mosienko et al., 2015; Teschemacher
et al., 2015). The greatest controversy involves why neu-
rons would even need lactate if there is glucose present.
There is no immediately obvious answer to this question
(Dienel, 2017). At least one important recent study per-
formed using state-of-the-art in vivo imaging in mouse
cortex provided evidence that there is a gradient of lactate
from astrocytes to neurons, which makes such transfer
physically possible (Machler et al., 2016).
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Another commonly recognized feature of astrocytes
is their capacity to store glucose in the form of glycogen.
Indeed, in the CNS glycogen is predominantly found in
astrocytes, although it is also present in minute amounts
in neurons (Phelps, 1972; Koizumi, 1974; Pfeiffer-
Guglielmi et al., 2003; Dienel, 2012). The glycosyl units
resulting from glycogen breakdown are fed into the gly-
colytic pathway of astrocytes; some of it becomes lactate,
which may be released into the extracellular space (Dienel
and Cruz, 2015). Storage of energy in the form of glyco-
gen may be important for brain resilience in situations
where glucose becomes scarce, although this depot has a
fairly small capacity. For example, it has been demon-
strated that brain glycogen levels are increased following
mild hypoxic preconditioning in vivo, resulting in signifi-
cant protection from brain damage caused by subsequent
hypoxic-ischemic injury (Brucklacher et al., 2002; Her-
zog et al., 2008; Canada et al., 2011; Evans et al., 2013).
It is interesting that more than 25 years ago it was postu-
lated that the main regulator of glycogenolysis in astro-
cytes is central noradrenaline (Stone and Ariano, 1989).
From the published transcriptomes (http://bioinf.
nl:8080/GOAD2/databaseSelectServlet), it appears that
the predominant receptor for noradrenaline on astrocytes
is the Gs-coupled b1 adrenoceptor subtype (Adrb1)
(Zhang et al., 2014); this is fully consistent with unpub-
lished observations from our laboratory. In contrast, b2
receptors are essentially all localized to microglia, while
b3 receptors are not expressed in the brain at any signifi-
cant level. Surprisingly, a recent study localized b2 recep-
tors to hippocampal astrocytes but not to microglia,
which calls for a further clarification of this fairly impor-
tant question (Gao et al., 2016). a2 adrenoceptors seem
to be also able to drive glycogenolysis in a pertussis toxin–
sensitive manner, implicating involvement of a Gi/o sig-
naling pathway (Hutchinson et al., 2011). Curiously,
adrenoceptors appear in transcriptomes at marginally low
levels (Zhang et al., 2014), but nevertheless, selective a1
agonists have a clear effect on astrocytic Ca21 in cortical
slices, and their activation leads to release of gliotransmit-
ters (Pankratov and Lalo, 2015). Hence, it is likely that
one of the key consequences of the activation of the locus
coeruleus (the key source of the front brain noradrena-
line), which is a landmark of arousal and behaviorally
engaged state of the brain, is activation of glycogenolysis.
It is also worth noting that the conventional view
on the mechanisms of lactate release from astrocytes—that
it necessarily requires MCTs—is no longer valid.
Channel-mediated release of lactate was reported,
although the nature of that channel has not yet been iden-
tified (Sotelo-Hitschfeld et al., 2015). Recently, we found
that lactate can be released via connexin hemichannels.
Hemichannel blockers strongly attenuated lactate release
triggered by transient hypoxia and by stimulation of
Schaffer collaterals in the hippocampus in brain slices. As
mentioned above, one trigger, which effectively opens
hemichannels, is lowering of extracellular Ca21 (Kara-
giannis et al., 2016). Hence, it is possible that dips in
extracellular Ca21 during episodes of neuronal activity
open hemichannels and cause release of not only
ATP but also lactate (Torres et al., 2012). For further dis-
cussion of the roles of lactate in astrocyte-to-neuronal
communication, see Barros (2013), Mosienko et al.
(2015), and Teschemacher et al. (2015).
Astrocytes Contribute to Control of Cerebral
Blood Flow
To maintain normal brain function, it is critical that
cerebral blood flow (CBF) is matched to the neuronal
metabolic needs. Apart from purely metabolic consider-
ations, this is critical because brain activity leads to release
of copious amounts of heat, which must be drained from
the activated areas to prevent overheating. Astrocytes are
the essential elements of the mechanism that controls
CBF (Howarth, 2014). However, it is still not clear how
astrocytes control the vasculature, although the unique
and close relationship of astrocytes with cerebral blood
vessels has been recognized since Ramon y Cajal’s time.
A popular hypothesis of astrocytic control of CBF in
response to neural activity has been that neuronally
released glutamate acts on astrocytic metabotropic gluta-
mate receptors (mGluRs) to raise astrocytic [Ca21]i, initi-
ating downstream production of arachidonic acid (AA)
followed by formation and release of vasoactive substances
(Zonta et al., 2003; Mulligan and MacVicar, 2004;
Takano et al., 2006; Attwell et al., 2010; Choi et al.,
2012). However, some studies have put this hypothesis
into question. For example, it has been shown that in
mature mice, mGluR5, which is usually expected to
mediate astrocytic Ca21 responses to glutamate, is down-
regulated, suggesting that this coupling mechanism might
be more relevant for the very young brain (Sun et al.,
2013). Other evidence suggests that neuron–glia signaling
may be mediated by neuronally released ATP acting on
glial P2Y receptors rather than via activation of mGluRs
by glutamate (Calcinaghi et al., 2011; Habbas et al., 2011;
Nizar et al., 2013; Sun et al., 2013). Group I mGluRs and
the ATP receptor P2Y1 are both G protein–coupled
receptors associated with Gaq signaling that induces Ca21
release from internal stores by generating IP3. However,
in mice where the astrocyte-specific subtype 2 of IP3
receptor was knocked out, neurovascular coupling
seemed to be preserved (Nizar et al., 2013). A recent
study by Mishra et al. might explain why release of Ca21
from stores does not affect neurovascular coupling (Mis-
hra et al., 2016). They provided evidence that astrocyte
[Ca21]i is raised not by release from intracellular stores
but by entry through ATP-gated channels. Alternative
hypotheses of astrocyte control of vessel diameter also
include the efflux of K1 through Ca21-activated K1
channels in astrocyte end-feet (Filosa et al., 2004). Some-
what in this vein is a recent study by Longden et al. that
described a mechanism present in brain capillaries and
operating via an inward-rectifier Kir2.1 channel (Longden
et al., 2017). The idea in that study is that this channel
can be activated by a local elevation in the extracellular
K1, resulting in further hyperpolarization of the
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endothelial cell. This creates a propagating wave of hyper-
polarization that travels to the upstream arterioles, causing
vasodilation and an increase in perfusion of activated areas
of the brain. This is an attractive idea because it could
help to tie together a number of previously made sugges-
tions, but it may need further support from other groups
working in this area.
The role of astrocyte [Ca21]i transients in the con-
trol of CBF in vivo during functional hyperemia remains
controversial. Although some studies argued that astro-
cytic Ca21 transients are not fast and frequent enough to
account for neurovascular coupling (Nizar et al., 2013),
the bulk of evidence shows convincingly that, at least at
the level of end-feet, responses occur within reasonable
time frames (Takano et al., 2006; Lind et al., 2013; Otsu
et al., 2015). Hence, we still do not know for certain
whether Ca21 transients in astrocytes really are critically
important for neuron-to-blood vessel coupling (Gurden
et al., 2006; Petzold et al., 2008; Schummers et al., 2008).
Irrespective of the role of Ca21, we have demonstrated
that rapid degradation of extracellular ATP and ADP by
viral vector–mediated expression of the enzyme trans-
membrane prostatic acid phosphatase drastically attenuates
BOLD fMRI responses in rat neocortex to stimulation of
somatic afferents (Wells et al., 2015). Even though in that
study the source of ATP was not identified, the bulk of
published studies point to astrocytes as the main sources
of extracellular ATP, which appears to be an essential
contributor to neurovascular coupling. Mishra and col-
leagues’ work suggested, though, that neuronal activity
also results in postsynaptic release of ATP by neurons,
which acts on ATP receptors on astrocytes (Mishra et al.,
2016). This process should have not been affected in our
experiments cited above (Wells et al., 2015), consistent
with the idea of astrocytes as the key source of ATP in
the case of neurovascular coupling.
Astrocytes and the Blood-Brain Barrier
Integrity of the blood-brain barrier (BBB) is funda-
mental to the well-being of neurons. The BBB is formed
by the endothelial cells connected by tight junctions, sur-
rounded by the basal lamina and sealed by the astrocyte
end-feet (Chow and Gu, 2015). Astrocytes are important
in the development and maintenance of BBB characteris-
tics in endothelial cells through the release of growth
factors like vascular endothelial growth factor (VEGF),
glia-derived neurotrophic factor, basic fibroblast growth
factor, and angiopoietin 1 (Dehouck et al., 1990; Rubin
et al., 1991; Hayashi et al., 1997; Haseloff et al., 2005;
Alvarez et al., 2013). These factors are important in the
formation of tight junctions, expression of relevant
enzymes, and polarization of the transporters (Wong
et al., 2013).
Disruption of BBB is a common feature of various
neurological disorders, such as cerebral ischemia, trauma,
glioblastoma, stroke, multiple sclerosis, epilepsy,
Alzheimer disease, and Parkinson disease, all of which are
accompanied by changes in the permeability of the BBB
and phenotypical changes of both endothelial cells and
astrocytes (Daneman, 2012; Alvarez et al., 2013; Cabezas
et al., 2014). Reactive gliosis, which typically follows
damage and accompanies BBB disruption, has an addi-
tional detrimental effect on the barrier function and neu-
ronal survival (Daneman, 2012; Obermeier et al., 2013;
Cabezas et al., 2014).
Astrocytes Defend Against Oxidative Stress
The mammalian CNS is particularly prone to dam-
aging effects of reactive oxygen species (ROS) because of
its high rate of oxidative metabolism and large fatty acid
content in myelin and other membranes (Belanger et al.,
2011). The unsaturated carbon–carbon bonds, needed to
ensure sufficient fluidity of the fatty acid side chains of the
phospholipids, are most susceptible to oxidative damage
by ROS (Dringen, 2000). ROS cause breakdown of a
large number of lipids and proteins. Because the reduction
of molecular oxygen by the respiratory chain is never
complete, ROS are always produced and need to be neu-
tralized. For further information, see the reviews by
Kimelberg and Nedergaard (2010), Gandhi and Abramov
(2012), Kim et al. (2015), and Gebicki (2016).
Astrocytes possess a much more effective defense
system against ROS than neurons (Wilson, 1997). There-
fore, cooperation of astrocytes with neurons is essential
for neuronal resilience against ROS (Belanger and Magis-
tretti, 2009). This idea is supported by a large number of
studies demonstrating that when cultured in the presence
of astrocytes, neurons are much more resistant to toxic
concentrations of nitric oxide, hydrogen peroxide, or
superoxide anions combined with nitric oxide or iron
(Langeveld et al., 1995; Lucius and Sievers, 1996; Tanaka
et al., 1999; Chen et al., 2001; Fujita et al., 2009).
Greater activity of ROS-detoxifying enzymes
(including glutathione [GSH] S-transferase, GSH peroxi-
dase, and catalase) and significantly higher levels of anti-
oxidant molecules (such as GSH, ascorbate, and vitamin
E) in astrocytes contribute to their ability to improve the
survival of neurons. In addition, astrocytes may also pre-
vent generation of free radicals by redox active metals, as
they participate in metal sequestration in the brain (Makar
et al., 1994; Huang and Philbert, 1995; Dringen et al.,
1999).
GSH is the most potent intrinsic antioxidant mole-
cule in the brain. As a tripeptide comprising the amino
acids glutamate, cysteine, and glycine, GSH is generated
by the successive actions catalyzed by g-glutamyl cysteine
ligase and GSH synthetase. Since intracellular glutamate
and glycine concentrations are relatively high, cysteine
appears to be the rate-limiting substrate for GSH synthesis
(Dringen, 2000). Extracellular cysteine is readily auto-
oxidized to cystine. Cystine uptake is mediated by cys-
tine/glutamate exchange transporter (xCT), which is
expressed primarily on astrocytes (Qiang et al., 2004; Seib
et al., 2011). Astrocytes then reduce it back to cysteine,
which is used to synthesize GSH, and consequently
release it into the extracellular space. GSH acts against
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ROS either by directly reacting with ROS or as a sub-
strate for GHS S-transferase or GSH peroxidase (Dringen,
2000). Although neurons also can synthesize GSH, they
depend on astrocytes for the supply of cysteine because
they are not very efficient in using extracellular cystine as
a cysteine precursor.
Ascorbic acid, the reduced form of vitamin C, is
another key antioxidant in the CNS. Ascorbic acid is syn-
thesized in the liver of most mammals. However, higher
primates, including humans, lack the functional enzyme
for the final step of synthesis, rendering them dependent
on exogenous sources of ascorbic acid (Nishikimi et al.,
1992; Lachapelle and Drouin, 2011). This dietary depen-
dence led to its categorization as a vitamin. Ascorbic acid
is concentrated in the brain (Spector and Lorenzo, 1973).
It is believed that ascorbic acid may be released from glial
reservoirs into the extracellular space, from where it is
taken up by neurons. In neurons, ascorbic acid scavenges
ROS generated during periods of high activity leading to
formation of the oxidized form dehydroascorbic acid,
which is released from neurons and taken up by astrocytes
(Wilson, 1997; Covarrubias-Pinto et al., 2015). Astrocytes
reduce dehydroascorbic acid back to ascorbic acid and
either use it themselves or release it into the extracellular
space. This recycling of ascorbate is another good exam-
ple of cooperation between astrocytes and neurons in
antioxidant defense (Covarrubias-Pinto et al., 2015).
Ascorbic acid has also been implicated in regulation of the
astrocyte–neuron lactate shuttle (Castro et al., 2009).
During glutamatergic synaptic activity, neurons produce
glutamate, which stimulates ascorbic acid release from
astrocytes. Ascorbic acid then enters into neurons and,
within the cell, can inhibit glucose consumption and
stimulate lactate transport. Imbalance of ascorbic acid
homeostasis has been demonstrated in several neurode-
generative disorders (Shaw, 2005; Acuna et al., 2013;
Warner et al., 2015). Ascorbic acid deficiency exacerbated
oxidative stress–induced neuronal death during neurode-
generation (Kim et al., 2015). Based on these consider-
ations, ascorbic acid has been tested as a neuroprotective
agent in humans for treatment of various neurodegenera-
tive diseases including Parkinson disease, amyotrophic lat-
eral sclerosis, and Huntington disease (Fitzgerald et al.,
2013; Covarrubias-Pinto et al., 2015). One of the major
problems with the application of ascorbic acid in neuro-
protective therapy is its rapid oxidation in tissues.
Astrocytes Assist Synapse Formation and
Maintenance
Astrocytes play an essential role in the development
of the nervous system by regulating formation, matura-
tion, maintenance, and stability of synapses (Guillamon-
Vivancos et al., 2015). Growing axons are directed
toward their targets by astrocyte-derived guide molecules,
such as tenascin C and proteoglycans (Powell and Geller,
1999). In the absence of glia, cultured retinal ganglion
cells developed little synaptic activity, which was 100
times higher when they were co-cultured with astrocytes,
and the increase was due to the formation of additional
synapses (Pfrieger and Barres, 1997). This increase in the
number of synapses was mediated by the astrocyte-
secreted factor, thrombospondin, an important matrix
molecule induced by purinergic signaling (Christopherson
et al., 2005; Risher and Eroglu, 2012). Thrombospondins
are a family of five homologous proteins. Astrocytes
express at least four types of thrombospondins during
development and following damage to brain tissue.
Thrombospondins facilitate formation of ultrastructurally
normal excitatory synapses at both presynaptic and post-
synaptic levels (Barres, 2008; Guillamon-Vivancos et al.,
2015). In addition to thrombospondins, cholesterol has
also been shown to be an important astrocytic factor for
synapse maturation. CNS neurons produce enough cho-
lesterol to survive and grow, but the formation of numer-
ous mature synapses demands additional amounts, which
are provided by astrocytes (Mauch et al., 2001; Ferris
et al., 2017; Van Deijk et al., 2017). Astrocytes also par-
ticipate in formation of the inhibitory synapses (Elmariah
et al., 2005). Therefore, it is plausible that astrocytes
might help restore synapses after injury (Emirandetti
et al., 2006; Tyzack et al., 2014) and represent a cellular
target for treatments aimed at promoting posttraumatic
plasticity and recovery. However, it is important to
acknowledge recent data demonstrating that astrocytes,
when pathologically activated by microglial cytokines,
can in fact have a detrimental effect on synapse formation
and/or maintenance (Longden et al., 2017).
It is thought that astrocytes are also involved in the
elimination of synapses in the CNS, the process that
underlies the fine tuning and plasticity of neuronal inputs
(Barres, 2008). This may be achieved by secretion of cer-
tain factors or proteolytic enzymes, which demolish the
extracellular matrix and reduce the stability of the synaptic
contact (Stevens et al., 2007; Verkhratsky et al., 2016).
Subsequently, astroglial processes may enter the former
synaptic cleft and literally substitute the synapse. It has
been suggested that astrocytes play a role in synaptic prun-
ing via Draper/Megf10 and Merk/integrin alpha(v)beta5
phagocytic pathways (Barres, 2008) and release of signals
that induce expression of the C1q protein, which activates
the classical complement pathway (Stevens et al., 2007).
Contribution of glia to formation and elimination of syn-
apses is one of the hot topics in today’s neuroscience.
Astrocytes Produce and Release a Variety of
Growth Factors and Other Trophic Molecules
Although it is generally accepted that co-cultured
astrocytes have “trophic” action on neurons, and that
they synthesize and release a range of molecules that can
be classified as trophic factors (e.g., brain-derived neuro-
trophic factor, VEGF), it is not clear whether any such
factors are exclusive to astrocytes. In this regard, trans-
forming growth factors (TGF)-b1 and TGF-b2 are prob-
ably among the best-documented candidates (Dhandapani
et al., 2003), and they may be responsible for the neuro-
protective effect of estrogens (Dhandapani and Brann,
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2003; see review by Gomes et al., 2005). Meteorin is
another example of a “trophic” factor involved in
astrocyte-to-neuron signaling. It was first identified as a
retinoic acid–responding gene suggested to be involved in
glial differentiation and regulation of axonal extension
(Nishino et al., 2004). Meteorin is long peptide (291
amino acids in the mouse) and is highly expressed by
Bergman glia in the cerebellum but also by astrocytes and
some discrete neuronal populations (Jorgensen et al.,
2009). In addition to the effects on glia and neurons, it is
implicated in the maturation of the BBB by stimulating
endothelial cells (Park et al., 2008). Recently, Lee et al.
found that Meteorin is upregulated in reactive astrocytes
in a photothrombotic ischemia mouse model and func-
tions as a negative feedback effector in reactive gliosis
(Lee et al., 2015). However, the cellular receptor(s) for
Meteorin is still unknown.
Astrocytes Improve Viability and Maturation of
Stem Cell–Derived Neurons
Human-induced pluripotent stem cell (hiPSC)-
derived neurons currently attract a lot of attention as
invaluable tools for modeling disease and as potential
means of therapy (An et al., 2012; Israel et al., 2012;
Chen et al., 2014; Zhang et al., 2017). HiPSCs provide
an unlimited source of genetically personalized cells of
various phenotypes, including neurons with a diminished
risk of immunorejection (Grskovic et al., 2011; Ichida
and Kiskinis, 2015). However, one of the critical con-
cerns that limits application of hiPSC-derived neurons is
their long-term functional stability. When cultured in the
absence of astrocytes, such neurons lack the adequate
environment and usually can only survive short-term. As
described earlier, it has long been recognized that astro-
cytes are essential partners of neurons and produce
numerous diffusible and nondiffusible neuron-supporting
signals and trophic factors (Barres, 2008)
Extensive experimental evidence demonstrates that
astrocytes play a critical role in promoting both
morphological and functional maturation of human neu-
rons derived from hiPSCs (Roy et al., 2006; Pasca et al.,
2015). For example, the presence of astrocytes signifi-
cantly enhanced neuronal dendritic complexity, the
expression of ionic channels and neurotransmitter recep-
tors, and the frequency and amplitude of synaptic events
in hiPSC-induced neurons (Tang et al., 2013). In another
study, co-culture of rat astrocytes with hiPSC-derived
neurons facilitated long-term survival of hiPSC-derived
neurons for more than 3 months and spontaneous firing
activity. Moreover, the presence of astrocytes protected
the neurons from damage, and they had elongated neu-
rites, contrasting with the damaged neurites in the
absence of astrocytes (Odawara et al., 2014). Other exam-
ples include embryonic stem cell–derived motor neurons
in mice, which were stabilized by culturing them on an
astrocytic “feeder” layer (Bryson et al., 2014). These and
many other observations show that astrocytes are crucial
partners to the induced neurons and justify the need for a
better understanding of this close relationship.
ASTROCYTES CAN SOMETIMES
BE “BAD GUYS”
As described above, astrocytes normally play a neuropro-
tective role, but, upon pathological stimuli, they can
release a range of cytotoxic mediators, including ROS,
reactive nitrogen species, proinflammatory cytokines, and
chemokines (Benveniste, 1992; Rama Rao and Kielian,
2015). These mediators are detrimental to neurons and
ultimately result in neuronal dysfunction and promote
neuronal cell death. Astrocytes respond to all forms of
injury and disease in the CNS through a process referred
to as reactive astrogliosis. Studies over the past 20 years
provide compelling evidence that reactive astrogliosis is
not simply an all-or-nothing phenomenon but, rather, is a
finely graded continuum of molecular, cellular, and func-
tional changes that range from subtle alterations in gene
expression to glial scar formation. These changes can
exert both beneficial (Anderson et al., 2016) and
Fig. 1. Summary of neuroprotective mechanisms residing in astrocytes discussed in this review.
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detrimental effects (Liddelow et al., 2017) in a context-
dependent manner regulated by many potential signaling
events. Reactive transformation of astrocytes is beyond
the scope of this review, but there have been some excel-
lent reviews published on this topic in recent years
(Burda and Sofroniew, 2014; Pekny and Pekna, 2014;
Pekny et al., 2014; Liu and Chopp, 2015; Filous and Sil-
ver, 2016; Pekny et al., 2016). Here we only want to
emphasize one recent high-profile study, which focused
attention on the mechanisms by which activated (reac-
tive) astrocytes may compromise neuronal networks
(Liddelow et al., 2017). Liddelow et al. used a model
whereby astrocytes are activated by the inflammatory
stimulus lipopolysaccharide (LPS). LPS injections
induced in astrocytes upregulation of many genes of the
classical complement cascade, and the authors ascribed a
neurotoxic phenotype, the so-called A1 state, to this
transformation. In contrast, ischemic insults lead to upre-
gulation of many of the factors with trophic activity, and
this state, termed A2, was postulated to be neuroprotec-
tive. The neurotoxic A1 phenotype was not the result of
a direct action of LPS on astrocytes but required a step
mediated by microglia, which is sensitive to LPS. Trans-
formation into the A1 phenotype seemed remarkably sta-
ble, rendering astrocytes unable to properly support
neuronal functions and synaptogenesis. Currently, the
identity of the “benevolent” A2 phenotype is much less
clear, as is how, in relation to these two proposed states,
various populations of resting astrocytes can be classified.
The study also suggested that genomic profiling reveals a
much more complex picture than just two clearly
defined states. Multiple papers where astrocytes were
used in vitro to support neurones, including stem cell–
derived neurones, show that on the whole, astrocytes are
extremely important for the well-being of neurones,
even though cultured astrocytes are always “reactive” to
some extent. We do not know whether their supportive
effects could be in all cases matched to the “beneficial
A2” genetic profile, leaving the possibility that the spe-
cific means by which astrocytes support neurons might
be very different in each particular case.
TARGETING ASTROCYTES:
PERSPECTIVES FOR THEIR
THERAPEUTIC POTENTIAL
Considering that astrocytes may act as a double-edged
sword, exerting both detrimental and neuroprotective
effects, it is conceivable that enhancing their beneficial
roles while minimizing their deleterious effects holds con-
siderable therapeutic potential for treatment of neurologi-
cal diseases. We recently reviewed and highlighted some
of the potentially targetable processes in astrocytes, which
might be of interest for future drug development (Liu
et al., 2017).
CONCLUDING REMARKS
In this brief review, we show that astrocytes actively sup-
port and protect neurons against toxic and traumatic
insults (summarized in Fig. 1). Harnessing the natural
capacity of astrocytes to protect neurons could be seen as
a promising therapeutic strategy aimed at eventually
improving neuronal function or resilience (Liu et al.,
2017). Recent revelations of the role of astroglia in the
flux of macromolecules or ions in the brain (termed
“glymphatic system”) have opened a new range of mech-
anisms by which astrocytes may contribute to the well-
being of the brain by clearance of potentially pathogenic
molecules during sleep or, in fact, by a contribution to
the sleep–wakefulness control (Xie et al., 2013; Ding
et al., 2016). We believe that many of the mechanisms
that astrocytes employ to assist neuronal networks repre-
sent potential opportunities for therapies aimed at pro-
cesses localized in astrocytes, rather than neurons.
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